Mycobacterium tuberculosis (Mtb) currently infects ~1/4 of the world’s population, kills ~1.5 million annually, and there are many strains that are multidrug resistant, thus investigating potential novel antibiotic targets for Mtb is essential. We have been systematically discovering the activity for and characterizing the Nudix hydrolases from Mtb as potential drug targets due to their ability to hydrolyze substrates involved in important metabolic and pathogenic processes. One Nudix hydrolase from Mtb that we have been studying is the ADP-ribose hydrolase Rv1700. ADP-ribose can spontaneously modify macromolecules; uncontrolled ADP-ribosylation due to excess ADP-ribose is detrimental to the cell, and thus Rv1700 may help control this process. Some ADP-ribose hydrolases have been shown to confer tellurite resistance. Currently, we are investigating the tellurite resistance of E. coli containing Rv1700 compared to wildtype E. coli. We would like to use tellurite resistance as a phenotypic marker for ADP-ribose hydrolase activity in vivo.

Rv1700 ADP-ribose hydrolase from Mycobacterium tuberculosis

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.